https://www.thebiointel.com/ Independent editorial intelligence platform serving biotech CEOs, investors, and strategic operators with signal, not noise. en-us Mon, 07 Sep 2026 14:20:21 GMT https://www.thebiointel.com/article/proteomic-clocks-show-lower-biological-age-across-six-models-in-rentosertib-phase-2a-trial-extending-aging-endpoints-into-ipf-drug-development https://www.thebiointel.com/article/proteomic-clocks-show-lower-biological-age-across-six-models-in-rentosertib-phase-2a-trial-extending-aging-endpoints-into-ipf-drug-development Biotech Innovation Mon, 07 Sep 2026 13:01:08 GMT https://www.thebiointel.com/article/adarx-files-for-ipo-to-fund-three-clinical-sirna-programs-extending-2026-biotech-listing-run https://www.thebiointel.com/article/adarx-files-for-ipo-to-fund-three-clinical-sirna-programs-extending-2026-biotech-listing-run Healthcare Investment Mon, 07 Sep 2026 07:01:11 GMT https://www.thebiointel.com/article/massbio-and-scbio-select-10-startups-for-drive-extending-early-stage-support-to-capital-starved-founders https://www.thebiointel.com/article/massbio-and-scbio-select-10-startups-for-drive-extending-early-stage-support-to-capital-starved-founders Healthcare Investment Sun, 06 Sep 2026 07:00:48 GMT https://www.thebiointel.com/article/tactical-athletes-get-new-cardiovascular-guidance-expanding-care-standards-across-4-million-workers https://www.thebiointel.com/article/tactical-athletes-get-new-cardiovascular-guidance-expanding-care-standards-across-4-million-workers Regulatory & Policy Sat, 05 Sep 2026 19:01:03 GMT https://www.thebiointel.com/article/novartis-reports-pelacarsen-phase-3-miss-in-8323-patients-leaving-lpa-field-open https://www.thebiointel.com/article/novartis-reports-pelacarsen-phase-3-miss-in-8323-patients-leaving-lpa-field-open Biotech Innovation Sat, 05 Sep 2026 07:00:58 GMT https://www.thebiointel.com/article/truist-says-biotech-rebound-reached-136-billion-in-deals-as-financing-and-fda-risks-ease https://www.thebiointel.com/article/truist-says-biotech-rebound-reached-136-billion-in-deals-as-financing-and-fda-risks-ease Healthcare Investment Fri, 04 Sep 2026 19:01:21 GMT https://www.thebiointel.com/article/menarini-signs-664-million-bofanglutide-deal-giving-gan-lee-a-39-country-european-route https://www.thebiointel.com/article/menarini-signs-664-million-bofanglutide-deal-giving-gan-lee-a-39-country-european-route Biopharmaceutical Industry Fri, 04 Sep 2026 19:01:21 GMT https://www.thebiointel.com/article/invivyd-names-marc-elia-ceo-ahead-of-vyd2311-phase-3-covid-readout https://www.thebiointel.com/article/invivyd-names-marc-elia-ceo-ahead-of-vyd2311-phase-3-covid-readout Biopharmaceutical Industry Fri, 04 Sep 2026 13:02:21 GMT https://www.thebiointel.com/article/stat-reports-lindsay-clancy-case-highlights-fragmented-u-s-care-and-postpartum-coordination-gaps https://www.thebiointel.com/article/stat-reports-lindsay-clancy-case-highlights-fragmented-u-s-care-and-postpartum-coordination-gaps Regulatory & Policy Fri, 04 Sep 2026 13:02:21 GMT https://www.thebiointel.com/article/egenesis-reports-two-pig-kidney-recipients-later-received-human-donor-organs-easing-a-key-xenotransplant-concern https://www.thebiointel.com/article/egenesis-reports-two-pig-kidney-recipients-later-received-human-donor-organs-easing-a-key-xenotransplant-concern Biotech Innovation Fri, 04 Sep 2026 07:01:24 GMT https://www.thebiointel.com/article/fda-opens-tempo-pilot-to-four-generative-ai-devices-creating-a-limited-early-market-path https://www.thebiointel.com/article/fda-opens-tempo-pilot-to-four-generative-ai-devices-creating-a-limited-early-market-path Regulatory & Policy Fri, 04 Sep 2026 07:01:24 GMT https://www.thebiointel.com/article/ionis-wins-fda-approval-for-zanvastro-in-alexander-disease-opening-its-first-independent-neurology-launch https://www.thebiointel.com/article/ionis-wins-fda-approval-for-zanvastro-in-alexander-disease-opening-its-first-independent-neurology-launch Biopharmaceutical Industry Fri, 04 Sep 2026 01:01:05 GMT https://www.thebiointel.com/article/arpa-h-commits-up-to-125m-for-give-rna-manufacturing-network-backing-distributed-personalized-production https://www.thebiointel.com/article/arpa-h-commits-up-to-125m-for-give-rna-manufacturing-network-backing-distributed-personalized-production Regulatory & Policy Thu, 03 Sep 2026 19:01:19 GMT https://www.thebiointel.com/article/pfizer-transfers-pf-08046031-to-medicus-in-up-to-1b-plus-deal-extending-seagen-asset-recycling https://www.thebiointel.com/article/pfizer-transfers-pf-08046031-to-medicus-in-up-to-1b-plus-deal-extending-seagen-asset-recycling Biopharmaceutical Industry Thu, 03 Sep 2026 19:01:19 GMT https://www.thebiointel.com/article/gsk-bets-up-to-1-295-billion-on-hutchmed-hmpl-a830-extending-its-asia-deal-push https://www.thebiointel.com/article/gsk-bets-up-to-1-295-billion-on-hutchmed-hmpl-a830-extending-its-asia-deal-push Biopharmaceutical Industry Thu, 03 Sep 2026 13:01:22 GMT https://www.thebiointel.com/article/ultragenyx-misses-phase-3-aspire-in-angelman-syndrome-prompting-expense-reduction-review https://www.thebiointel.com/article/ultragenyx-misses-phase-3-aspire-in-angelman-syndrome-prompting-expense-reduction-review Biotech Innovation Thu, 03 Sep 2026 13:01:22 GMT https://www.thebiointel.com/article/fda-raises-foreign-trial-scrutiny-tightening-standards-as-china-research-expands https://www.thebiointel.com/article/fda-raises-foreign-trial-scrutiny-tightening-standards-as-china-research-expands Regulatory & Policy Thu, 03 Sep 2026 07:00:59 GMT https://www.thebiointel.com/article/teva-reports-phase-2a-tev-408-win-in-celiac-disease-extending-its-il-15-bet https://www.thebiointel.com/article/teva-reports-phase-2a-tev-408-win-in-celiac-disease-extending-its-il-15-bet Biotech Innovation Thu, 03 Sep 2026 01:01:18 GMT https://www.thebiointel.com/article/fortrea-buys-worldwide-early-phase-unit-for-45-million-expanding-texas-capacity https://www.thebiointel.com/article/fortrea-buys-worldwide-early-phase-unit-for-45-million-expanding-texas-capacity Biopharmaceutical Industry Thu, 03 Sep 2026 01:01:18 GMT https://www.thebiointel.com/article/uniqure-files-amt-130-for-fda-and-uk-review-reopening-a-huntingtons-gene-therapy-path-after-fda-reversal https://www.thebiointel.com/article/uniqure-files-amt-130-for-fda-and-uk-review-reopening-a-huntingtons-gene-therapy-path-after-fda-reversal Regulatory & Policy Wed, 02 Sep 2026 19:01:26 GMT https://www.thebiointel.com/article/sec-and-fda-sign-three-year-information-sharing-pact-tightening-biopharma-insider-trading-scrutiny https://www.thebiointel.com/article/sec-and-fda-sign-three-year-information-sharing-pact-tightening-biopharma-insider-trading-scrutiny Regulatory & Policy Wed, 02 Sep 2026 19:01:26 GMT https://www.thebiointel.com/article/amgen-loses-new-uk-tavneos-starts-as-fda-hearing-fight-continues https://www.thebiointel.com/article/amgen-loses-new-uk-tavneos-starts-as-fda-hearing-fight-continues Regulatory & Policy Wed, 02 Sep 2026 13:02:15 GMT https://www.thebiointel.com/article/novartis-signs-up-to-3-2-billion-alteogen-deal-expanding-its-subcutaneous-delivery-options https://www.thebiointel.com/article/novartis-signs-up-to-3-2-billion-alteogen-deal-expanding-its-subcutaneous-delivery-options Biopharmaceutical Industry Wed, 02 Sep 2026 13:02:15 GMT https://www.thebiointel.com/article/arsenalbio-cuts-99-jobs-pivot-in-vivo-car-t-halting-ex-vivo-clinical-development https://www.thebiointel.com/article/arsenalbio-cuts-99-jobs-pivot-in-vivo-car-t-halting-ex-vivo-clinical-development Biopharmaceutical Industry Wed, 02 Sep 2026 07:01:22 GMT https://www.thebiointel.com/article/biopharma-reverse-mergers-jump-1600-percent-in-q3-giving-private-companies-faster-route-public https://www.thebiointel.com/article/biopharma-reverse-mergers-jump-1600-percent-in-q3-giving-private-companies-faster-route-public Healthcare Investment Wed, 02 Sep 2026 07:01:22 GMT https://www.thebiointel.com/article/medtronic-recalls-bravo-cf-capsule-delivery-devices-after-184-serious-injuries-reviving-a-prior-failure-mode https://www.thebiointel.com/article/medtronic-recalls-bravo-cf-capsule-delivery-devices-after-184-serious-injuries-reviving-a-prior-failure-mode Medical Technology Wed, 02 Sep 2026 01:00:49 GMT https://www.thebiointel.com/article/roche-strikes-up-to-1-53-billion-simcere-deal-for-sim0660-extending-its-asia-licensing-run https://www.thebiointel.com/article/roche-strikes-up-to-1-53-billion-simcere-deal-for-sim0660-extending-its-asia-licensing-run Biopharmaceutical Industry Tue, 01 Sep 2026 19:01:17 GMT https://www.thebiointel.com/article/alumis-misses-lupus-phase-2b-endpoints-but-advances-envudeucitinib-toward-phase-3-in-ifngs-high-sle https://www.thebiointel.com/article/alumis-misses-lupus-phase-2b-endpoints-but-advances-envudeucitinib-toward-phase-3-in-ifngs-high-sle Biotech Innovation Tue, 01 Sep 2026 19:01:17 GMT https://www.thebiointel.com/article/gsk-starts-phase-3-flum3ha-b-3na-after-phase-2-flu-immunogenicity-win https://www.thebiointel.com/article/gsk-starts-phase-3-flum3ha-b-3na-after-phase-2-flu-immunogenicity-win Biopharmaceutical Industry Tue, 01 Sep 2026 13:01:16 GMT https://www.thebiointel.com/article/boston-scientific-halts-imager-ii-catheter-sales-after-two-serious-injuries https://www.thebiointel.com/article/boston-scientific-halts-imager-ii-catheter-sales-after-two-serious-injuries Medical Technology Tue, 01 Sep 2026 13:01:16 GMT https://www.thebiointel.com/article/takeda-protagonist-win-mimrylo-approval-polycythemia-vera-broader-than-expected-launch https://www.thebiointel.com/article/takeda-protagonist-win-mimrylo-approval-polycythemia-vera-broader-than-expected-launch Biopharmaceutical Industry Tue, 01 Sep 2026 07:01:17 GMT https://www.thebiointel.com/article/electra-files-nasdaq-ipo-fund-ipsoprubart-phase-2-3-program-shlh https://www.thebiointel.com/article/electra-files-nasdaq-ipo-fund-ipsoprubart-phase-2-3-program-shlh Healthcare Investment Tue, 01 Sep 2026 07:01:17 GMT https://www.thebiointel.com/article/eli-lilly-strikes-up-to-2-875-billion-merida-deal-extending-its-autoantibody-strategy-in-immunology https://www.thebiointel.com/article/eli-lilly-strikes-up-to-2-875-billion-merida-deal-extending-its-autoantibody-strategy-in-immunology Biopharmaceutical Industry Tue, 01 Sep 2026 01:01:14 GMT https://www.thebiointel.com/article/novartis-and-bristol-myers-halt-autoimmune-car-t-studies-after-immune-events-pressuring-a-fast-moving-cd19-field https://www.thebiointel.com/article/novartis-and-bristol-myers-halt-autoimmune-car-t-studies-after-immune-events-pressuring-a-fast-moving-cd19-field Biotech Innovation Tue, 01 Sep 2026 01:01:14 GMT https://www.thebiointel.com/article/biontech-genentech-halt-bnt122-phase-2-after-more-deaths-in-vaccine-arm https://www.thebiointel.com/article/biontech-genentech-halt-bnt122-phase-2-after-more-deaths-in-vaccine-arm Biopharmaceutical Industry Sat, 29 Aug 2026 19:00:51 GMT https://www.thebiointel.com/article/wainua-phase-3-setback-clouds-ttr-silencers-strengthening-the-case-for-attr-cm-stabilizers https://www.thebiointel.com/article/wainua-phase-3-setback-clouds-ttr-silencers-strengthening-the-case-for-attr-cm-stabilizers Biopharmaceutical Industry Sat, 29 Aug 2026 13:00:58 GMT https://www.thebiointel.com/article/nature-papers-detail-two-prime-editing-routes-for-large-dna-insertions-without-double-strand-breaks https://www.thebiointel.com/article/nature-papers-detail-two-prime-editing-routes-for-large-dna-insertions-without-double-strand-breaks Biotech Innovation Sat, 29 Aug 2026 07:00:58 GMT https://www.thebiointel.com/article/ausperbio-raises-120-million-series-c-to-push-ahb-137-through-phase-3-in-chronic-hepatitis-b https://www.thebiointel.com/article/ausperbio-raises-120-million-series-c-to-push-ahb-137-through-phase-3-in-chronic-hepatitis-b Healthcare Investment Sat, 29 Aug 2026 01:01:09 GMT https://www.thebiointel.com/article/juul-gets-fda-clearance-for-juul2-with-optional-age-verification-reopening-its-u-s-device-pipeline https://www.thebiointel.com/article/juul-gets-fda-clearance-for-juul2-with-optional-age-verification-reopening-its-u-s-device-pipeline Regulatory & Policy Sat, 29 Aug 2026 01:01:09 GMT https://www.thebiointel.com/article/teva-sets-57-5-million-floor-for-bioxcel-assets-tying-more-value-to-bxcl501-fda-timing https://www.thebiointel.com/article/teva-sets-57-5-million-floor-for-bioxcel-assets-tying-more-value-to-bxcl501-fda-timing Biopharmaceutical Industry Fri, 28 Aug 2026 19:01:15 GMT https://www.thebiointel.com/article/lilly-wins-mounjaro-cardiovascular-risk-approval-matching-novo-in-a-key-glp-1-market https://www.thebiointel.com/article/lilly-wins-mounjaro-cardiovascular-risk-approval-matching-novo-in-a-key-glp-1-market Regulatory & Policy Fri, 28 Aug 2026 19:01:15 GMT https://www.thebiointel.com/article/genentech-pays-45-million-upfront-for-dualitybio-adcs-targeting-post-topoisomerase-resistance https://www.thebiointel.com/article/genentech-pays-45-million-upfront-for-dualitybio-adcs-targeting-post-topoisomerase-resistance Healthcare Investment Fri, 28 Aug 2026 13:01:16 GMT https://www.thebiointel.com/article/astrazeneca-amgen-post-tezspire-eoe-phase-3-win-opening-a-dosing-based-challenge-to-dupixent https://www.thebiointel.com/article/astrazeneca-amgen-post-tezspire-eoe-phase-3-win-opening-a-dosing-based-challenge-to-dupixent Biopharmaceutical Industry Fri, 28 Aug 2026 13:01:16 GMT https://www.thebiointel.com/article/rfk-jr-faces-new-scrutiny-over-samoa-letters-complicating-vaccine-policy-credibility https://www.thebiointel.com/article/rfk-jr-faces-new-scrutiny-over-samoa-letters-complicating-vaccine-policy-credibility Regulatory & Policy Fri, 28 Aug 2026 01:01:51 GMT https://www.thebiointel.com/article/roivant-wins-lisraya-approval-in-dermatomyositis-adding-a-once-daily-pill-for-a-rare-autoimmune-disease https://www.thebiointel.com/article/roivant-wins-lisraya-approval-in-dermatomyositis-adding-a-once-daily-pill-for-a-rare-autoimmune-disease Biopharmaceutical Industry Fri, 28 Aug 2026 01:01:51 GMT https://www.thebiointel.com/article/osivax-licenses-gc-flu-rights-outside-japan-and-korea-advancing-a-single-shot-flu-combination-plan https://www.thebiointel.com/article/osivax-licenses-gc-flu-rights-outside-japan-and-korea-advancing-a-single-shot-flu-combination-plan Biopharmaceutical Industry Thu, 27 Aug 2026 19:01:28 GMT https://www.thebiointel.com/article/generate-biomedicines-drops-after-gb-0895-posters-leak-early-exposing-new-phase-1-copd-and-asthma-data https://www.thebiointel.com/article/generate-biomedicines-drops-after-gb-0895-posters-leak-early-exposing-new-phase-1-copd-and-asthma-data AI in Drug Discovery Wed, 02 Sep 2026 22:36:27 GMT https://www.thebiointel.com/article/hospitals-plot-push-to-rework-1-trillion-in-medicaid-cuts-even-as-trump-law-stands https://www.thebiointel.com/article/hospitals-plot-push-to-rework-1-trillion-in-medicaid-cuts-even-as-trump-law-stands Regulatory & Policy Thu, 27 Aug 2026 13:01:29 GMT https://www.thebiointel.com/article/flagships-profound-signs-up-to-35-million-gates-foundation-pact-for-preeclampsia-targets https://www.thebiointel.com/article/flagships-profound-signs-up-to-35-million-gates-foundation-pact-for-preeclampsia-targets AI in Drug Discovery Thu, 27 Aug 2026 13:01:29 GMT https://www.thebiointel.com/article/akeso-reports-phase-3-ivonescimab-survival-win-in-biliary-tract-cancer-extending-its-case-beyond-lung-cancer https://www.thebiointel.com/article/akeso-reports-phase-3-ivonescimab-survival-win-in-biliary-tract-cancer-extending-its-case-beyond-lung-cancer Biopharmaceutical Industry Thu, 27 Aug 2026 07:01:30 GMT